Skip to main content

Advertisement

SpringerLink
Log in

p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study

  • ORIGINAL ARTICLE
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Hormone receptor status has been one of the most important factors in predicting the response to endocrine therapy in breast cancer patients. However, half of those patients with estrogen receptor-positive tumors do not respond to endocrine therapy. There have been no universal factors for predicting resistance to endocrine therapy in this population. Recently, p53 status has been extensively used as a predictive factor for response to systemic therapy, because tumor cells lacking p53 function do not respond to systemic therapy due to a failure in apoptosis. We therefore studied the relationship between the efficacy of endocrine therapy and biological factors, including p53.

Methods

The expression of p53, Ki67, and human epidermal growth factor receptor (HER)2 was examined by immunostaining in the primary tumors of 53 patients who received endocrine therapy for recurrent or advanced breast cancer. The following clinical factors were also analyzed: site treated, disease-free interval, and response to first-line endocrine therapy. To evaluate the significance of these factors, time to endocrine therapy failure (TTEF), or the total duration of sequential endocrine therapies was adopted as representing the clinical outcome.

Results

The median TTEF was 16.1 months (range, 2.5–89.9 months). Multivariate analysis showed significantly reduced TTEF associated with no response to first-line endocrine therapy (P = 0.006 and P = 0.002 in all patients and in recurrent patients, respectively) and associated with positive p53 expression (P = 0.066 and P = 0.004, respectively).

Conclusion

p53 expression status was a significant molecular marker as well as the response to first-line endocrine therapy for predicting TTEF in recurrent breast cancer with hormone-sensitive disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. DR Ciocca R Elledge (2000) ArticleTitleMolecular markers for predicting response to tamoxifen in breast cancer patients Endocrine 13 1–10 Occurrence Handle11051041 Occurrence Handle10.1385/ENDO:13:1:1 Occurrence Handle1:CAS:528:DC%2BD3cXms1ygurg%3D

    Article  PubMed  CAS  Google Scholar 

  2. CG Kardinal (2002) Hormonal and endocrine therapy of breast cancer WL Donegan JS Spratt (Eds) Cancer of the breast, fifth edn Elsevier Science St. Louis 693–737

    Google Scholar 

  3. AE Ring PA Ellis (2002) ArticleTitlePredictors of response to systemic therapy in breast cancer Forum Genova 12 19–32 Occurrence Handle12634908

    PubMed  Google Scholar 

  4. CK Osborne J Shou S Massarweh et al. (2005) ArticleTitleCrosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer Clin Cancer Res 11 865–870

    Google Scholar 

  5. G Arpino SJ Green DC Allred et al. (2004) ArticleTitleHER2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study Clin Cancer Res 10 5670–5676 Occurrence Handle15355892 Occurrence Handle10.1158/1078-0432.CCR-04-0110 Occurrence Handle1:CAS:528:DC%2BD2cXntlOqtbY%3D

    Article  PubMed  CAS  Google Scholar 

  6. MJ Ellis A Coop B Singh et al. (2001) ArticleTitleLetrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 3808–3816 Occurrence Handle11559718 Occurrence Handle1:CAS:528:DC%2BD3MXnsVKqsbo%3D

    PubMed  CAS  Google Scholar 

  7. JM Dixon J Jackson M Hills et al. (2004) ArticleTitleAnastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status Eur J Cancer 40 2742–2747 Occurrence Handle15571956 Occurrence Handle10.1016/j.ejca.2004.08.025 Occurrence Handle1:CAS:528:DC%2BD2cXhtVahurjM

    Article  PubMed  CAS  Google Scholar 

  8. EM Berns JA Foekens R Vossen et al. (2000) ArticleTitleComplete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer Cancer Res 60 2155–2162 Occurrence Handle10786679 Occurrence Handle1:CAS:528:DC%2BD3cXivVaksb4%3D

    PubMed  CAS  Google Scholar 

  9. PL Fitzgibbons DL Page D Weaver et al. (2000) ArticleTitlePrognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 124 966–978 Occurrence Handle10888772 Occurrence Handle1:STN:280:DC%2BD3czptVKrtQ%3D%3D

    PubMed  CAS  Google Scholar 

  10. GN Hortobagyi (1998) ArticleTitleTreatment of breast cancer N Engl J Med 339 974–984 Occurrence Handle9753714 Occurrence Handle10.1056/NEJM199810013391407 Occurrence Handle1:CAS:528:DyaK1cXmslCitrY%3D

    Article  PubMed  CAS  Google Scholar 

  11. JL Hayward PP Carbone JC Heuson et al. (1977) ArticleTitleAssessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland Cancer 39 1289–1294 Occurrence Handle912660 Occurrence Handle10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F Occurrence Handle1:STN:280:CSeD383jslQ%3D

    Article  PubMed  CAS  Google Scholar 

  12. H de Haes M Olschewski M Kaufmann et al. (2003) ArticleTitleQuality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group J Clin Oncol 21 4510–4516 Occurrence Handle14610048 Occurrence Handle10.1200/JCO.2003.11.064 Occurrence Handle1:CAS:528:DC%2BD2cXpsVWqur4%3D

    Article  PubMed  CAS  Google Scholar 

  13. M Piccart LM Parker KI Pritchard (2003) ArticleTitleOestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer Ann Oncol 14 1017–1025 Occurrence Handle12853342 Occurrence Handle10.1093/annonc/mdg290 Occurrence Handle1:STN:280:DC%2BD3szitlCktQ%3D%3D

    Article  PubMed  CAS  Google Scholar 

  14. K Shimozuma H Sonoo K Ichihara (1995) ArticleTitleAnalysis of the factors influencing the quality of life of patients with advanced or recurrent breast cancer Surg Today 25 874–882 Occurrence Handle8574053 Occurrence Handle10.1007/BF00311752 Occurrence Handle1:STN:280:BymC28%2FgslU%3D

    Article  PubMed  CAS  Google Scholar 

  15. J Kurebayashi H Sonoo H Inaji et al. (2000) ArticleTitleEndocrine therapies for patients with recurrent breast cancer: predictive factors for responses to first- and second-line endocrine therapies Oncology 59 31–37 Occurrence Handle11096354 Occurrence Handle10.1159/000055285 Occurrence Handle1:CAS:528:DC%2BD3cXos1Omu78%3D

    Article  PubMed  CAS  Google Scholar 

  16. SG Archer A Eliopoulos D Spandidos et al. (1995) ArticleTitleExpression of ras parn21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy Br J Cancer 72 1259–1266 Occurrence Handle7577479 Occurrence Handle1:STN:280:BymD28bhsFc%3D

    PubMed  CAS  Google Scholar 

  17. RM Elledge S Green L Howes et al. (1997) ArticleTitlebcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study J Clin Oncol 15 1916–1922 Occurrence Handle9164202 Occurrence Handle1:CAS:528:DyaK2sXjsVCksL8%3D

    PubMed  CAS  Google Scholar 

  18. J Bergh T Norberg S Sjogren et al. (1995) ArticleTitleComplete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy Nat Med 1 1029–1034 Occurrence Handle7489358 Occurrence Handle10.1038/nm1095-1029 Occurrence Handle1:CAS:528:DyaK2MXosVGgu70%3D

    Article  PubMed  CAS  Google Scholar 

  19. R Silvestrini E Benini S Veneroni et al. (1996) ArticleTitlep53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients J Clin Oncol 14 1604–1610 Occurrence Handle8622078 Occurrence Handle1:STN:280:BymB3cfotl0%3D

    PubMed  CAS  Google Scholar 

  20. EM Berns JG Klijn MP Look et al. (2003) ArticleTitleCombined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer Clin Cancer Res 9 1253–1258 Occurrence Handle12684392 Occurrence Handle1:CAS:528:DC%2BD3sXislertrw%3D

    PubMed  CAS  Google Scholar 

  21. EM Berns JG Klijn WL van Putten et al. (1998) ArticleTitlep53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer J Clin Oncol 16 121–127 Occurrence Handle9440732 Occurrence Handle1:CAS:528:DyaK1cXmtlKgsA%3D%3D

    PubMed  CAS  Google Scholar 

  22. GM Horne JJ Anderson DG Tiniakos et al. (1996) ArticleTitlep53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry Br J Cancer 73 29–35 Occurrence Handle8554979 Occurrence Handle1:STN:280:BymC2cnlvFM%3D

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast and Endocrine Surgery, Faculty of Medical and Pharmaceutical Science, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan

    Kazuharu Kai & Hirotaka Iwase

  2. Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Japan

    Kazuharu Kai & Reiki Nishimura

  3. Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan

    Nobuyuki Arima & Haruhiko Miyayama

Authors
  1. Kazuharu Kai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reiki Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nobuyuki Arima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Haruhiko Miyayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hirotaka Iwase
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuharu Kai.

About this article

Cite this article

Kai, K., Nishimura, R., Arima, N. et al. p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol 11, 426–433 (2006). https://doi.org/10.1007/s10147-006-0601-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-006-0601-6

Key words

Search

Navigation